TY - JOUR T1 - The ocular findings related to oral bisphosphonate use JO - Archivos de la Sociedad Española de Oftalmología (English Edition) T2 - AU - Atar,S. AU - Yurttaser,S.O. AU - Demirhan,E. AU - Er,G. AU - Kuru,Ö. SN - 21735794 M3 - 10.1016/j.oftale.2022.06.006 DO - 10.1016/j.oftale.2022.06.006 UR - https://www.elsevier.es/en-revista-archivos-sociedad-espanola-oftalmologia-english-496-articulo-the-ocular-findings-related-oral-S2173579422000901 AB - ObjectiveWe aimed to investigate ocular involvement findings in female osteoporosis patients using oral bisphosphonate (BP). MethodsA total of 51 female osteoporosis patients aged 50–75 years using oral BP for at least one year for the study group and 64 age-matched non-osteoporosis female patients for the control group were included in the study. The BP type and exposure time were noted. The ophthalmic examination findings and measurements of the flare of the patients who received oral BP due to osteoporosis and the controls were evaluated. ResultsThe mean duration of BP use was 3.96 years. In the study group, it was detected four of 51 patients were diagnosed with meibomian gland dysfunction (MGD) (7.8%), seven of 102 eyes had erythematous, irregular, thickened lid margin or telangiectasia around the glandular orifices. There were no pathological findings on fundus examination. The mean value of measurements of the flare (ph/ms) was 7.90±7.96 in the study group, and 5.02±0.81 in the control group. When the mean values were compared, there was a significant difference between the two groups (P=.001). A significant difference was found in the mean value of measurements of the flare between the patients using alendronate, and ibandronate with the control group (P=.001; P=.005, respectively). ConclusionOur study showed that the flare in the anterior chamber associated with chronic ocular inflammation can be seen higher rate in patients using oral alendronate, and ibandronate compared to those who do not. Morever it can be said that oral BPs may cause similar ocular side effects like as intravascular BPs. ER -